首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1388197

痛風治療藥物市場、份額、市場規模、趨勢、產業分析報告：依藥物類別、疾病狀態、地區、細分市場預測，2023-2032

Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents); By Disease Condition; By Region; Segment Forecast, 2023 - 2032

出版日期: 2023年10月23日 | 出版商:

Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

根據 Polaris 市場研究的最新研究，到 2032 年，全球痛風藥物市場預計將達到 60.4 億美元。該報告提供了對當前市場動態的詳細見解，並對未來市場成長進行了分析。

隨著專注於再生療法的研究和開發的增加，生物製劑正在獲得認可。這些創新的治療方法在解決痛風的症狀和根本原因方面顯示出巨大的潛力。此外，影像方式的顯著進步提高了有效診斷和監測痛風的能力。

此外，對痛風及其危險因子的更好了解也提高了醫療專業人員和患者的認識。痛風主要發生在 40 歲以上的男性，他們的血液中尿酸含量較高。男性比女性更容易患痛風。過量的尿酸會形成針狀晶體，引起關節疼痛、發炎和疼痛。

這些綜合因素正在推動對有效痛風治療的需求。製藥公司和研究人員正在積極致力於開發新的和改進的治療方法，以解決痛風症狀和長期管理。目標是為患者提供緩解疼痛、減少發炎並防止痛風復發的標靶治療。

由於生活方式的改變和飲食因素，痛風在全球範圍內呈上升趨勢，且患者數量不斷增加。市場正在見證治療選擇的進步，包括新的藥物配方和組合，提供更高的療效和便利性。

此外，根據患者個別特徵客製化治療的個人化醫療方法也變得越來越流行。意識和診斷率的提高、技術的進步以及新興市場的擴張進一步促進了市場的成長。主要產業參與者之間的聯盟和合作也促進了痛風藥物的研究和開發。

痛風治療市場報告亮點

非類固醇類抗發炎藥（NSAIDs）領域以最高份額佔據市場主導地位。非類固醇類抗發炎藥 (NSAID) 廣泛使用、經濟高效且在嚴重痛風發作期間有效，使其成為減輕風濕性和非風濕性疾病發炎和疼痛的可行選擇，是首選藥物。

慢性病細分市場預計將佔據市場上最大的銷售份額。該領域的成長是由各種降尿酸藥物的推出以及新療法進入市場的潛力所推動的。

北美在市場上佔據主導地位，並打算在預測期內保持其主導地位。痛風影響著北美的許多人，光在美國估計就有 830 萬人，盛行率為 1% 至 4%。

主要發現
簡介
- 2019-2032 年按地區劃分的痛風治療藥物市場評估
痛風藥物市場 - 北美
- 北美：痛風藥物市場，依疾病狀況，2019-2032 年
- 北美：2019-2032 年痛風藥物市場，依藥物分類
- 痛風藥物市場 - 美國
- 痛風藥物市場 - 加拿大
痛風藥物市場 - 歐洲
- 歐洲：2019-2032 年痛風藥物市場，依疾病狀態
- 歐洲：2019-2032 年痛風藥物市場，依藥物分類
- 痛風藥物市場 - 英國
- 痛風藥物市場 - 法國
- 痛風藥物市場－德國
- 痛風藥物市場 - 義大利
- 痛風藥市場－西班牙
- 痛風藥物市場 - 荷蘭
- 痛風藥物市場 - 俄羅斯
痛風藥物市場 - 亞太地區
- 亞太地區：痛風藥物市場，依疾病狀況，2019-2032 年
- 亞太地區：痛風藥物市場，依藥物類別，2019-2032 年
- 痛風藥物市場－中國
- 痛風藥物市場 - 印度
- 痛風藥市場 - 馬來西亞
- 痛風藥物市場－日本
- 痛風藥物市場－印度尼西亞
- 痛風治療藥物市場－韓國
痛風藥物市場 - 中東和非洲
- 中東和非洲：2019-2032 年痛風藥物市場，依疾病狀況
- 中東和非洲：2019-2032 年痛風藥物市場，依藥物類別
- 痛風藥物市場－沙烏地阿拉伯
- 痛風藥物市場 - 阿拉伯聯合大公國
- 痛風藥物市場 - 以色列
- 痛風藥物市場 - 南非
痛風藥物市場 - 拉丁美洲
- 拉丁美洲：痛風藥物市場，依疾病狀況，2019-2032 年
- 拉丁美洲：痛風藥物市場，依藥物類別，2019-2032 年
- 痛風藥物市場 - 墨西哥
- 痛風藥物市場 - 巴西
- 痛風藥物市場－阿根廷

第 8 章競爭態勢

擴張與收購分析
- 放大
- 收購
夥伴關係/協作/協議/揭露

第 9 章公司簡介

Ablynx
Antares Pharma
Astellas Pharma
AstraZeneca
Boehringer Ingelheim
CymaBay Therapeutics
Eisai
Eli Lilly
GlaxoSmithKline
Horizon Pharma
JW Pharmaceutical
LG Life Sciences
Merck
Novartis
Novo Nordisk
Regeneron Pharmaceuticals
Sandoz（a subsidiary of Novartis）
Sanofi
Takeda Pharmaceuticals
Teijin Pharma
Vertex Pharmaceuticals

簡介目錄圖表

Product Code: PM1611

The global gout therapeutics market size is expected to reach USD 6.04 billion by 2032, according to a new study by Polaris market research. The report "Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents); By Disease Condition; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Biologics has a rising acceptance and increased research and development focused on regeneration therapies. These innovative treatment approaches show great promise in addressing gout's symptoms and underlying causes. Additionally, there have been significant advancements in imaging modalities, which have enhanced the ability to diagnose and monitor gout effectively.

Furthermore, a greater understanding of the disease and its risk factors leads to increased awareness among healthcare professionals and patients. Gout primarily affects men over 40 with high uric acid levels in their blood. Males are more susceptible to developing gout compared to females. Excessive uric acid leads to the formation of needle-like crystals, which can result in joint pain, inflammation, and soreness.

These combined factors have propelled the demand for effective gout therapeutics. Pharmaceutical companies and researchers are actively working to develop new and improved treatment options to address the symptoms and long-term management of gout. The aim is to provide patients with targeted therapies that alleviate pain, reduce inflammation, and prevent recurrent gout attacks.

Gout is growing globally due to lifestyle changes and dietary factors, expanding the patient pool. The market is witnessing advancements in treatment options, including new drug formulations and combinations, offering improved efficacy and convenience.

Additionally, personalized medicine approaches are gaining traction, tailoring treatments based on individual patient characteristics. Rising awareness and diagnosis rates, technological advancements, and expansion in emerging markets further contribute to the market's growth. Collaborations and partnerships among key industry players also facilitate research and development efforts in gout therapeutics.

Gout Therapeutics Market Report Highlights

NSAIDs segment dominated the market with highest share. Due to their widespread availability, cost-effectiveness, and efficacy during severe gout attacks, NSAIDs are the preferred first-line treatment for reducing inflammation and pain in rheumatic and non-rheumatic diseases.

Chronic segment anticipated to hold the largest revenue share of the market. The growth of this segment is fueled by the introduction of various urate-lowering drugs and the potential for new treatments to enter the market.

North America dominated the market and willing to maintain its dominance over the forecast period. Gout affects many people in North America, with an estimated 8.3 million individuals affected in the United States alone and a prevalence rate ranging from 1% to 4%.

The global key market players include: Ablynx, Antares Pharma, CymaBay Therapeutics, Astellas Pharma, AstraZeneca, Horizon Pharma, Boehringer Ingelheim, Merck, Eisai, Regeneron Pharmaceuticals, Eli Lilly and others.

Polaris market research has segmented the gout therapeutics market report based on drug class, disease condition, and region:

Gout Therapeutics, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate Lowering Agents

Gout Therapeutics, Disease Condition Outlook (Revenue - USD Billion, 2019 - 2032)

Acute
Chronic

Gout Therapeutics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Latin America
Argentina
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Gout Therapeutics Market Insights

4.1. Gout Therapeutics Market - Industry Snapshot
4.2. Gout Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Increasing prevalence of gout worldwide
  - 4.2.1.2. Continuous research and development activities
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Cost of treatment
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Gout Therapeutics Industry trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Gout Therapeutics Market, by Drug Class

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Gout Therapeutics, by Drug Class, 2019-2032 (USD Billion)
5.3. Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
- 5.3.1. Global Gout Therapeutics Market, by Non-steroidal Anti-Inflammatory Drugs (NSAIDs) by Region, 2019-2032 (USD Billion)
5.4. Corticosteroids
- 5.4.1. Global Gout Therapeutics Market, by Corticosteroids, by Region, 2019-2032 (USD Billion)
5.5. Colchicine
- 5.5.1. Global Gout Therapeutics Market, by Colchicine, by Region, 2019-2032 (USD Billion)
5.6. Urate Lowering Agents
- 5.6.1. Global Gout Therapeutics Market, by Urate Lowering Agents, by Region, 2019-2032 (USD Billion)

6. Global Gout Therapeutics Market, by Disease Condition

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
6.3. Acute
- 6.3.1. Global Gout Therapeutics Market, by Acute, by Region, 2019-2032 (USD Billion)
6.4. Chronic
- 6.4.1. Global Gout Therapeutics Market, by Chronic, by Region, 2019-2032 (USD Billion)

7. Global Gout Therapeutics Market, by Geography

7.1. Key findings
7.2. Introduction
- 7.2.1. Gout Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
7.3. Gout Therapeutics Market - North America
- 7.3.1. North America: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.3.2. North America: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.3.3. Gout Therapeutics Market - U.S.
  - 7.3.3.1. U.S.: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.3.3.2. U.S.: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.3.4. Gout Therapeutics Market - Canada
  - 7.3.4.1. Canada: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.3.4.2. Canada: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
7.4. Gout Therapeutics Market - Europe
- 7.4.1. Europe: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.4.2. Europe: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.3. Gout Therapeutics Market - UK
  - 7.4.3.1. UK: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.4.3.2. UK: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.4. Gout Therapeutics Market - France
  - 7.4.4.1. France: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.4.4.2. France: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.5. Gout Therapeutics Market - Germany
  - 7.4.5.1. Germany: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.4.5.2. Germany: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.6. Gout Therapeutics Market - Italy
  - 7.4.6.1. Italy: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.4.6.2. Italy: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.7. Gout Therapeutics Market - Spain
  - 7.4.7.1. Spain: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.4.7.2. Spain: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.8. Gout Therapeutics Market - Netherlands
  - 7.4.8.1. Netherlands: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.4.8.2. Netherlands: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.9. Gout Therapeutics Market - Russia
  - 7.4.9.1. Russia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.4.9.2. Russia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
7.5. Gout Therapeutics Market - Asia Pacific
- 7.5.1. Asia Pacific: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.5.2. Asia Pacific: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.3. Gout Therapeutics Market - China
  - 7.5.3.1. China: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.5.3.2. China: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.4. Gout Therapeutics Market - India
  - 7.5.4.1. India: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.5.4.2. India: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.5. Gout Therapeutics Market - Malaysia
  - 7.5.5.1. Malaysia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.5.5.2. Malaysia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.6. Gout Therapeutics Market - Japan
  - 7.5.6.1. Japan: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.5.6.2. Japan: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.7. Gout Therapeutics Market - Indonesia
  - 7.5.7.1. Indonesia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.5.7.2. Indonesia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.8. Gout Therapeutics Market - South Korea
  - 7.5.8.1. South Korea: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.5.8.2. South Korea: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
7.6. Gout Therapeutics Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.6.2. Middle East & Africa: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.6.3. Gout Therapeutics Market - Saudi Arabia
  - 7.6.3.1. Saudi Arabia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.6.3.2. Saudi Arabia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.6.4. Gout Therapeutics Market - UAE
  - 7.6.4.1. UAE: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.6.4.2. UAE: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.6.5. Gout Therapeutics Market - Israel
  - 7.6.5.1. Israel: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.6.5.2. Israel: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.6.6. Gout Therapeutics Market - South Africa
  - 7.6.6.1. South Africa: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.6.6.2. South Africa: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
7.7. Gout Therapeutics Market - Latin America
- 7.7.1. Latin America: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.7.2. Latin America: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.7.3. Gout Therapeutics Market - Mexico
  - 7.7.3.1. Mexico: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.7.3.2. Mexico: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.7.4. Gout Therapeutics Market - Brazil
  - 7.7.4.1. Brazil: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.7.4.2. Brazil: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.7.5. Gout Therapeutics Market - Argentina
  - 7.7.5.1. Argentina: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.7.5.2. Argentina: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. Ablynx
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. Antares Pharma
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
9.3. Astellas Pharma
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
9.4. AstraZeneca
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
9.5. Boehringer Ingelheim
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
9.6. CymaBay Therapeutics
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
9.7. Eisai
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
9.8. Eli Lilly
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
9.9. GlaxoSmithKline
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
9.10. Horizon Pharma
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
9.11. JW Pharmaceutical
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development
9.12. LG Life Sciences
- 9.12.1. Company Overview
- 9.12.2. Financial Performance
- 9.12.3. Product Benchmarking
- 9.12.4. Recent Development
9.13. Merck
- 9.13.1. Company Overview
- 9.13.2. Financial Performance
- 9.13.3. Product Benchmarking
- 9.13.4. Recent Development
9.14. Novartis
- 9.14.1. Company Overview
- 9.14.2. Financial Performance
- 9.14.3. Product Benchmarking
- 9.14.4. Recent Development
9.15. Novo Nordisk
- 9.15.1. Company Overview
- 9.15.2. Financial Performance
- 9.15.3. Product Benchmarking
- 9.15.4. Recent Development
9.16. Regeneron Pharmaceuticals
- 9.16.1. Company Overview
- 9.16.2. Financial Performance
- 9.16.3. Product Benchmarking
- 9.16.4. Recent Development
9.17. Sandoz (a subsidiary of Novartis)
- 9.17.1. Company Overview
- 9.17.2. Financial Performance
- 9.17.3. Product Benchmarking
- 9.17.4. Recent Development
9.18. Sanofi
- 9.18.1. Company Overview
- 9.18.2. Financial Performance
- 9.18.3. Product Benchmarking
- 9.18.4. Recent Development
9.19. Takeda Pharmaceuticals
- 9.19.1. Company Overview
- 9.19.2. Financial Performance
- 9.19.3. Product Benchmarking
- 9.19.4. Recent Development
9.20. Teijin Pharma
- 9.20.1. Company Overview
- 9.20.2. Financial Performance
- 9.20.3. Product Benchmarking
- 9.20.4. Recent Development
9.21. Vertex Pharmaceuticals
- 9.21.1. Company Overview
- 9.21.2. Financial Performance
- 9.21.3. Product Benchmarking
- 9.21.4. Recent Development

簡介目錄圖表

List of Tables

Table 1 Global Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 2 Global Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 3 Gout Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
Table 4 North America: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 5 North America: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 6 U.S.: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 7 U.S.: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 8 Canada: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 9 Canada: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 10 Europe: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 11 Europe: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 12 UK: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 13 UK: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 14 France: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 15 France: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 16 Germany: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 17 Germany: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 18 Italy: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 19 Italy: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 20 Spain: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 21 Spain: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 22 Netherlands: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 23 Netherlands: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 24 Russia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 25 Russia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 26 Asia Pacific: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 27 Asia Pacific: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 28 China: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 29 China: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 30 India: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 31 India: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 32 Malaysia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 33 Malaysia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 34 Japan: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 35 Japan: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 36 Indonesia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 37 Indonesia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 38 South Korea: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 39 South Korea: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 40 Middle East & Africa: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 41 Middle East & Africa: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 42 Saudi Arabia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 43 Saudi Arabia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 44 UAE: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 45 UAE: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 46 Israel: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 47 Israel: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 48 South Africa: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 49 South Africa: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 50 Latin America: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 51 Latin America: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 52 Mexico: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 53 Mexico: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 54 Brazil: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 55 Brazil: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 56 Argentina: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 57 Argentina: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)

List of Figures

Figure 1 Global Gout Therapeutics Market, 2019-2032 (USD Billion)
Figure 2 Integrated Ecosystem
Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
Figure 4 Market by Geography
Figure 5 Porter's Five Forces
Figure 6 Market by Disease Condition
Figure 7 Global Gout Therapeutics Market, by Disease Condition, 2022 & 2032 (USD Billion)
Figure 8 Market by Drug Class
Figure 9 Global Gout Therapeutics Market, by Drug Class, 2022 & 2032 (USD Billion)
Figure 10 Gout Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
Figure 11 Strategic Analysis - Gout Therapeutics Market